“Cardiovascular Adverse Event Risk in Rheumatoid Arthritis Patients Treated with JAK Inhibitor Tofacitinib versus TNF Inhibitors: a Systematic Review, Meta Analysis, and Meta Regression”, JIMKI, p. 4, Dec. 2025, doi: 10.53366/jimki.vi.949.